122 related articles for article (PubMed ID: 34268074)
1. Predictive value of lncRNA LOC100505851 in breast cancer in the neoadjuvant setting.
Sha R; Wu Z; Xu Y; Sheng X; Wang Y; Yuan C; Peng J; Xu S; Zhou L; Lin Y; Yin W; Lu J
Gland Surg; 2021 Jun; 10(6):1899-1909. PubMed ID: 34268074
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
3. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
4. LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Gan FJ; Li Y; Xu MX; Zhou T; Wu S; Hu K; Li Y; Sun SH; Luo Q
Cancer Biomark; 2021; 32(3):339-351. PubMed ID: 34151842
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.
Wang J; Li D; Wang B; Wu Y
Breast Cancer Res Treat; 2013 Sep; 141(2):213-24. PubMed ID: 24036660
[TBL] [Abstract][Full Text] [Related]
7. A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer.
Bi Z; Qiu PF; Zhang Y; Song XG; Chen P; Xie L; Wang YS; Song XR
Front Oncol; 2021; 11():779140. PubMed ID: 34938660
[TBL] [Abstract][Full Text] [Related]
8. Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy.
Liang Z; Wang X; Dong K; Li X; Qin C; Zhou H
Biomed Res Int; 2021; 2021():5575704. PubMed ID: 33977106
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy.
Sha R; Xu Y; Yuan C; Sheng X; Wu Z; Peng J; Wang Y; Lin Y; Zhou L; Xu S; Zhang J; Yin W; Lu J
EBioMedicine; 2021 Sep; 71():103560. PubMed ID: 34482070
[TBL] [Abstract][Full Text] [Related]
10. A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.
Sun M; Liu X; Xia L; Chen Y; Kuang L; Gu X; Li T
Biochem Pharmacol; 2021 Jul; 189():114285. PubMed ID: 33069665
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
Takada M; Higuchi T; Tozuka K; Takei H; Haruta M; Watanabe J; Kasai F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Ogawa S; Kaneko Y
BMC Cancer; 2013 May; 13():241. PubMed ID: 23679233
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
14. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
15. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
[TBL] [Abstract][Full Text] [Related]
16. Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy.
Zheng YZ; Li JY; Ning LW; Xie N
Breast Cancer (Dove Med Press); 2022; 14():475-487. PubMed ID: 36578908
[TBL] [Abstract][Full Text] [Related]
17. A prognostic eight-lncRNA expression signature in predicting recurrence of ER-positive breast cancer receiving endocrine therapy.
Tang J; Cui Q; Zhang D; Kong D; Liao X; Ren J; Gong Y; Wu G
J Cell Physiol; 2020 May; 235(5):4746-4755. PubMed ID: 31663114
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy.
Wu Z; Zhang L; Xu S; Lin Y; Yin W; Lu J; Sha R; Sheng X; Zhou L; Lu J
Cancer Cell Int; 2019; 19():78. PubMed ID: 30976202
[TBL] [Abstract][Full Text] [Related]
19. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
20. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Fernandez-Martinez A; Krop IE; Hillman DW; Polley MY; Parker JS; Huebner L; Hoadley KA; Shepherd J; Tolaney S; Henry NL; Dang C; Harris L; Berry D; Hahn O; Hudis C; Winer E; Partridge A; Perou CM; Carey LA
J Clin Oncol; 2020 Dec; 38(35):4184-4193. PubMed ID: 33095682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
